CALLIDITAS THERAPEUTICS

Loading quotes...

Forecast

Buy	2
Hold	1
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2022, CALLIDITAS THERAPEUTICS has already paid €51.04 in dividends. The last payout was in June 2022.

Financials

In the last year, CALLIDITAS THERAPEUTICS had revenue of €108.22M and net profit of -€41.8M

(EUR)	2023	YoY
Revenue	108.22M	50.76%
Gross profit	101.31M	43.86%
Net profit	-41.8M	13.41%
EBITDA	-32.98M	1.42%

Fundamentals

Metric	Value
Market capitalization	€1.01B
Number of shares	54.03M
52-week high/low	€18.81 - €7.28
Dividends	No
Beta	1.46
P/E ratio	-23.94
PEG ratio	0.41
P/B ratio	33.34
P/S ratio	9.31

Company profile

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.